FDA questioned statistical methods and benefit-risk assessment for Capricor Therapeutics, which is seeking approval and trading on the Nasdaq exchange.
2 reports, 1 independent
Updated Aug 6
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA questioned statistical methods and benefit-risk assessment for Capricor Therapeutics, which is seeking approval and trading on the Nasdaq exchange.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Rocket is utilizing Nasdaq for investor evaluation and the FDA reviewed Phase 2 efficacy data for its product RP-A501.
- Iovance Biotherapeutics listed its stock on Nasdaq and received Fast Track designation from the FDA.
- FDA raised concerns over cell therapy evidence for Capricor Therapeutics, causing a sharp drop in stock price.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- Cardiol Therapeutics Inc. is listed on Nasdaq and is developing therapy for an FDA-approved indication.